Form 4: Sensei Biotherapeutics CEO Granted Stock Options

Sensei Biotherapeutics CEO, John Celebi, was granted stock options to purchase 355,000 shares of common stock.

Summary

• John Celebi, the President and CEO of Sensei Biotherapeutics, Inc., was granted stock options on December 20, 2024.
• The options allow him to purchase 355,000 shares of Sensei Biotherapeutics common stock at an exercise price of $0.4499 per share.
• The stock options vest on December 1, 2025, contingent upon Mr. Celebi's continued service with the company.
• The options expire on December 19, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and can be seen as a positive sign of aligning management's interests with shareholders. However, it also represents potential dilution if the options are exercised.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
• The size of the grant (355,000 shares) would need to be compared to grants at similar-sized biotech companies to assess its relative value.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• The CEO is incentivized to improve company performance, which benefits shareholders.

Key Dates

Keywords

stock options, Sensei Biotherapeutics, CEO, John Celebi, SNSE, executive compensation, Form 4